Formulation for Anti-α4β7 antibody

TW202637213APending Publication Date: 2026-09-16TAKEDA PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114144541
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2011-10-06
Filing Date
2012-05-02
Publication Date
2026-09-16

Smart Images

  • Figure TWG2TA001076435_001
    Figure TWG2TA001076435_001
  • Figure TWG2TA001076435_002
    Figure TWG2TA001076435_002
  • Figure TWG2TA001076435_003
    Figure TWG2TA001076435_003
Patent Text Reader

Abstract

Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
Need to check novelty before this filing date? Find Prior Art